BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications
International Journal of Molecular Sciences · 16.04.2025 · 26 (8) · 3757
DOI: 10.3390/ijms26083757 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.04.2025. Verfasst von Hiba Mechahougui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, Geneva University Hospital (HUG), 1205 Geneva, Switzerland. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Protein Kinase Inhibitors, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BRAF mutations are critical drivers in cancers such as melanoma, colorectal cancer, and non-small-cell lung cancer. The most common mutation, BRAF V600E, is a key therapeutic target. Targeted treatments with BRAF and MEK inhibitors have significantly improved progression-free and overall survival in melanoma patients. However, in cancers like metastatic colorectal cancer, BRAF mutations are associated with poor outcomes due to aggressive disease behavior and resistance to conventional chemotherapy. Despite progress, resistance to BRAF/MEK inhibitors remains a major challenge, often driven by secondary mutations in the mitogen-activated protein kinase (MAPK) pathway, activation of alternative pathways such as phosphoinositide 3-kinases (PI3Ks)/protein kinase B (AKT), or changes in the tumor microenvironment. These challenges have motivated ongoing research into combining BRAF inhibitors with immunotherapies to enhance and prolong treatment effectiveness. Future research must also account for the role of the cancer’s tissue of origin, as the biological context significantly influences response to targeted therapies, highlighting the need for a deeper understanding of tumor biology, micro-environment, and genetics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Department, Geneva University Hospital (HUG), 1205 Geneva, Switzerland.
- Cancer Research Center of Lyon, CNRS UMR5286, Inserm U1052, University of Lyon, 69100 Lyon, France.
- Clinique Générale Beaulieu, 1206 Geneva, Switzerland.
ORCID-Profile: Hiba Mechahougui, James Gutmans
Zitieren
APA
Mechahougui, H., Gutmans, J., Gouasmi, R., Smekens, L., & Friedlaender, A. (2025). BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications. International Journal of Molecular Sciences, 26(8), 3757. https://doi.org/10.3390/ijms26083757
Vancouver
Mechahougui H, Gutmans J, Gouasmi R, Smekens L, Friedlaender A. BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications. International Journal of Molecular Sciences. 2025;26(8):3757. doi:10.3390/ijms26083757
BibTeX
@article{Mechahougui2025,
author = {Mechahougui, Hiba and Gutmans, James and Gouasmi, Roumaïssa and Smekens, Laure and Friedlaender, Alex},
title = {BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {8},
pages = {3757},
doi = {10.3390/ijms26083757}
}
EUVIMED